Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17806570 | 0.85 | KIF11 (0.56) | KIF11ARLMNAALDH1A1HPGD | |
| SCHEMBL1584633 | 0.84 | DGAT1 (0.42) | KIF11ARDGAT1CHEK1EGLN2 | |
| SCHEMBL19786225 | 0.82 | DGAT1 (0.32) | KIF11ARDGAT1 | |
| SCHEMBL18745830 | 0.81 | AR (0.40) | ARLMNASMN1; SMN2DGAT1CHEK1 | |
| SCHEMBL2553743 | 0.79 | DGAT1 (0.50) | KIF11ALDH1A1SMN1; SMN2NPSR1DGAT1 | |
| SCHEMBL4365411 | 0.79 | TSHR (0.34) | KIF11LMNAALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL14946756 | 0.79 | GRM5 (0.39) | KIF11LMNAALDH1A1HPGDDGAT1 | |
| SCHEMBL30841758 | 0.79 | DGAT1 (0.50) | KIF11ALDH1A1SMN1; SMN2NPSR1DGAT1 | |
| SCHEMBL11533562 | 0.79 | CHEK1 (0.43) | KIF11ARALDH1A1NPSR1DGAT1 | |
| SCHEMBL20858055 | 0.78 | AR (0.33) | ARCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11834424-B2 | Compounds useful as chaperone-mediated autophagy modulators | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2023-12-05 | — | — | US | disclosed |
| US-11832510-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230373972-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230373972-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230321056-A1 | Methods for Treating Metastasis with Cathepsin C Inhibitors | Shanghai Institute of nutrition and health, Chinese Academy of Sciences (CN) | 2023-10-12 | — | — | US | disclosed |
| US-7585888-B2 | Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585868-B2 | Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-09-08 | — | — | US | disclosed |
| US-20090197877-A1 | Antibacterial Compositions | PROLYSIS LTD. (GB) | 2009-08-06 | — | — | US | disclosed |
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ARRAY BIOPHARMA, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090069400-A1 | Indole Sulfonamide Modulators of Progesterone Receptors | ELI LILLY AND COMPANY | 2009-03-12 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-7384947-B2 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2008-06-10 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | MTOR, PI4KA, PIK3CA | KIF11 4257/4885AR 2775/4885LMNA 4705/4885 |
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | KIF11 3410/4885AR 363/4885LMNA 3446/4885 |
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR5A, HTR4 | KIF11 3116/4885AR 251/4885LMNA 4504/4885 |
| US-11834424-B2 | Compounds useful as chaperone-mediated autophagy modulators | SQSTM1, HSPA5, ATG7 | KIF11 2234/4885AR 4446/4885LMNA 3765/4885 |
| US-11832510-B2 | Organic electroluminescent materials and devices | OSBP, OCIAD2, OCIAD1 | KIF11 2437/4885AR 3376/4885LMNA 2853/4885 |
| US-20090197877-A1 | Antibacterial Compositions | CYCS, COX6C, INTS6 | KIF11 4788/4885AR 93/4885LMNA 3994/4885 |
| US-20230321056-A1 | Methods for Treating Metastasis with Cathepsin C Inhibitors | MMP8, CTSS, CTSF | KIF11 1604/4885AR 3441/4885LMNA 655/4885 |
| US-12030904-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | KIF11 4039/4885AR 4609/4885LMNA 1033/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | KIF11 1631/4885AR 3407/4885LMNA 1340/4885 |
| US-20090069400-A1 | Indole Sulfonamide Modulators of Progesterone Receptors | PGR, NPSR1, PRLHR | KIF11 3844/4885AR 32/4885LMNA 4147/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | KIF11 3419/4885AR 1721/4885LMNA 3477/4885 |
| US-20230373972-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | F7, F11, HABP2 | KIF11 524/4885AR 4386/4885LMNA 1614/4885 |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | KIF11 4039/4885AR 4609/4885LMNA 1033/4885 |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | KIF11 2375/4885AR 1284/4885LMNA 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.